AUTL
Autolus Therapeutics plc
Healthcare — Biotechnology
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Price History
Fundamentals
| Market Cap | $425.83M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.66 |
| EPS (TTM) | $-1.09 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -29.62% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $8.71 |
| Analysts | 9 |
| Next Earnings | Aug 11, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 61.7 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.70 |
| 52-Week Low | $1.18 |
| 50-Day Avg | $1.59 |
| 200-Day Avg | $1.53 |
| Avg Volume | $1.39M |
| Volume | 479.6K |
Performance Analysis
BULLISHAUTL shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jun 30, 2026 21:08 UTC
Back to Screener Export Report